Inovio Pharmaceuticals 2020 DNA Medicines Investor Presentation

Inovio presents its DNA medicine platform and clinical pipeline as of May 2020, highlighting achievements including the first DNA medicine in Phase 3 trials (VGX-3100) for cervical dysplasia and first dMAb in Phase 1 for Zika. The company showcases immune response data from over 2,000 patients and its proprietary smart device delivery technology.